Ascendis Pharma A (ASND) Total Liabilities (2012 - 2026)

Ascendis Pharma A (ASND) has 15 years of Total Liabilities data on file, last reported at $1.8 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 34.79% year-over-year to $1.8 billion; the trailing twelve-month figure through Mar 2026 stood at $1.8 billion (up 34.79% YoY), and the FY2025 full-year result was $1.7 billion, up 22.63% from the prior year.
• Total Liabilities advanced to $1.8 billion in Q1 2026, from $1.7 billion in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $1.8 billion in Q1 2026 to a low of $767.2 million in Q2 2022.
• A 5-year average of $1.2 billion and a median of $1.1 billion in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities jumped 303.36% in 2022 and increased 7.73% in 2023, its largest moves.
• Tracing ASND's Total Liabilities over 5 years: stood at $843.1 million in 2022, then grew by 23.95% to $1.0 billion in 2023, then jumped by 31.42% to $1.4 billion in 2024, then rose by 24.2% to $1.7 billion in 2025, then gained by 4.0% to $1.8 billion in 2026.
• Business Quant data shows ASND's Total Liabilities at $1.8 billion in Q1 2026, $1.7 billion in Q4 2025, and $1.6 billion in Q3 2025.